Castren & Snellman advised FIT Biotech Oy in its listing on the First North market maintained by the Helsinki Stock Exchange. FIT Biotech is a biopharma company established in 1995. It focuses on DNA vaccines and gene therapy.

In the initial public offering, the company raised gross funds of EUR 3.5 million. After the offering, the company has 395 shareholders. Trading in the company's shares on First North began today.

The company's team of advisers was headed by our partner Merja Kivelä and included counsel Hanna Paloheimo and associates Anna-Maarit Laurila, Paula Tuononen and Aksu Tuominen.